Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-11-20
1999-09-28
Degen, Nancy
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 245, 536 231, 536 243, 536 241, 435 6, 435375, C07H 2104, C12Q 168
Patent
active
059590971
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of MEK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEK2. Methods of using these compounds for modulation of MEK2 expression and for treatment of diseases associated with expression of MEK2 are provided.
REFERENCES:
patent: 5149797 (1992-09-01), Pederson
patent: 5770713 (1998-06-01), Imbach
patent: 5789573 (1998-08-01), Baker
patent: 5856462 (1996-10-01), Agrawal
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48 Feb. 1998.
Eugene Uhlmann and Anusch Peyman, Antisense Oligonucleotides: A new Therapeutic Principle, Chemical Reviews, pp. 545-546 Jun. 1990
Trisha Gura, Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995.
Stanley Crooke, Antisense '97: A roundtable on the state of the industry, Nature Biotechnology, p. 522, Jun. 1997.
Alessi et al., PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J Biol Chem, 1995, 270:27489-27494.
Amundadottir et al., Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes, Oncogene, 1998, 16:737-746.
Brott et al., MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues, Cell Growth Differ., 1993, 4:921-929.
Gupta et al., Differential effect of glucose deprivation on MAPK activation in drug sensitive human breast carcinoma MCF-7 and multidrug resistant MCF-7/ADR cells, Mol. Cell Biochem., 1997, 170:23-30.
Kosako et al., Mitogen-activated protein kinase kinase is required for the mos-induced metaphase arrest, J Biol Chem, 1994, 269:28354-28358.
Mohr et al., Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059, Proc. Natl. Acad. Sci. U S A, 1998, 95:5045-5050.
Robinson et al., Mitogen-activated protein kinase pathways, Curr. Opin. Cell Biol., 1997, 9:180-186.
Schmidt et al., Increased MAPK expression and activity in primary human hepatocellular carcinoma, Biochem Biophys Res Commun, 1997, 236-54-58.
Seger et al., Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells, J. Biol. Chem., 1992, 267:14373-14381.
Seger et al., The MAPK Signaling cascade, The FASEB Journal 1995, 9:726-735.
Zheng et al., Cloning and characterization of two distinct human extracellular signal--regulated kinase activator kinases, MEK1 and MEK2, J. Biol. Chem., 1993, 268-11435-11439.
Cowsert Lex M.
Monia Brett P.
Degen Nancy
Epps Janet L.
ISIS Pharmaceuticals Inc.
LandOfFree
Antisense modulation of MEK2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of MEK2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of MEK2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-704764